阿霉素洗脱微球TACE对比传统TACE治疗肝癌的Meta分析

摘要

Objective To conduct a Meta-analysis for assessing the therapeutic efficacy and safety of doxorubicin-eluting bead transcatheter arterial chemoembolization (DEB-TACE) vs conventional TACE (C-TACE) in the treatment of hepatoeellular carcinoma (HCC).Methods The relevant studies on DEB-TACE and C-TACE for HCC were searched from PubMed,Web of Science and CK1N databases.The tumor responds and adverse events in the selected studies were analyzed with RevMan5.0 statistical software.Moreover,publication bias was assessed by a funnel plot.Results Thirteen studies with 1 325 HCC patients were finally included in this analysis.The tumor response to DEB-TACE was better than that to C-TACE (OR:2.28;95％CI [1.75,2.96];P＜0.001 0).The risk of adverse events in DEB-TACE group was also lower than that in C-TACE group (RR:0.56;95％ CI [0.32,0.97];P=0.04).Conclusion Compared with C-TACE,DEB-TACE is more effective and has lower risk of adverse events in the treatment of HCC.%目的:采用Meta分析方法评价和比较阿霉素洗脱微球TACE(DEB-TACE)与传统TACE(C-TACE)治疗肝癌的有效性和安全性.方法:从PubMed、Web of Science和CKIN数据库检索DEB-TACE和C-TACE治疗肝癌的文献.分别采用RevMan5.0软件分析肿瘤反应和不良事件,漏斗图分析出版偏倚.结果:共有13个研究1 325例肝癌患者纳入分析.DEB-TACE组的肿瘤反应率优于C-TACE组(OR:2.28;95％CI 1.75,2.96];P＜0.0010).DEB-TACE组的不良事件风险低于C-TACE组(RR:0.56;95％CI[0.32,0.97];P=0.04).结论:和C-TACE对比,DEB-TACE治疗肝癌更有效、不良事件风险更低.